drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular immunotherapy)
drug_description
Investigational apheresis-derived therapeutic immune cell product administered as a single IV infusion (dose-escalation 5.0×10^7 to 3.0×10^9 cells) for refractory/recurrent/metastatic digestive tract cancers; adoptive cellular immunotherapy intended to recognize a tumor-associated target protein and mediate T/NK-like cytotoxic killing of malignant cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Adoptive Transfer
drug_category
CULTURED CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Adoptive transfer of apheresis-derived immune effector cells that are expanded/activated ex vivo to recognize a tumor-associated target protein and kill malignant cells via T/NK cell–like cytotoxic mechanisms (e.g., perforin/granzyme-mediated lysis).
drug_name
BGT007 Injection
nct_id_drug_ref
NCT06104241